Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial
Open Access
- 1 September 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0131390
Abstract
Albumin treatment of ischemic stroke was associated with cardiopulmonary adverse events in previous studies and a low incidence of intracranial hemorrhage. We sought to describe the neurological and cardiopulmonary adverse events in the ALIAS Part 2 Multicenter Trial. Ischemic stroke patients, aged 18–83 and a baseline NIHSS ≥ 6, were randomized to treatment with ALB or saline control within 5 hours of stroke onset. Neurological adverse events included symptomatic intracranial hemorrhage, hemicraniectomy, neurological deterioration and neurological death. Cardiopulmonary adverse events included pulmonary edema/congestive heart failure, acute coronary syndromes, atrial fibrillation, pneumonia and pulmonary thromboembolism. Among 830 patients, neurological and cardiopulmonary adverse events were not differentially associated with poor outcome between ALB and saline control subjects. The rate of symptomatic intracranial hemorrhage in the first 24h was low overall (2.9%, 24/830) but more common in the ALB treated subjects (RR = 2.4, CI95 1.01–5.8). The rate of pulmonary edema/CHF in the first 48h was 7.9% (59/830) and was more common among ALB treated subjects (RR = 10.7, CI95 4.3–26.6); this complication was expected and was satisfactorily managed with mandated diuretic administration and intravenous fluid guidelines. Troponin elevations in the first 48h were common, occurring without ECG change or cardiac symptoms in 52 subjects (12.5%). ALB therapy was associated with an increase in symptomatic ICH and pulmonary edema/congestive heart failure but this did not affect final outcomes. Troponin elevation occurs routinely in the first 48 hours after acute ischemic stroke. ClincalTrials.gov NCT00235495Keywords
This publication has 26 references indexed in Scilit:
- Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer’s lactate on blood loss and coagulation after cardiac surgeryBritish Journal of Anaesthesia, 2013
- Troponin Elevation Predicts Atrial Fibrillation in Patients with Stroke or Transient Ischemic AttackJournal of Stroke and Cerebrovascular Diseases, 2013
- Troponin T in Acute Ischemic StrokeThe American Journal of Cardiology, 2013
- Highly Sensitive Troponin T in Patients with Acute Ischemic StrokeEuropean Neurology, 2012
- Albumin Therapy Enhances Collateral Perfusion after Laser-Induced Middle Cerebral Artery Branch Occlusion: A Laser Speckle Contrast Flow StudyJournal of Cerebral Blood Flow & Metabolism, 2012
- The Albumin in Acute Stroke Part 1 TrialStroke, 2011
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary Microvascular ThrombosisStroke, 2008
- Cardiac Troponin T Elevation After Stroke: Relationships Between Elevated Serum Troponin T, Stroke Location, and PrognosisJournal of Clinical Neurology, 2008
- Diffusion-Weighted Magnetic Resonance Imaging Confirms Marked Neuroprotective Efficacy of Albumin Therapy in Focal Cerebral IschemiaStroke, 1998